Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines

Abstract

Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigenpresenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications. © 2013 Landes Bioscience.